Vanda Pharmaceuticals Inc. (VNDA)

NASDAQ: VNDA · Real-Time Price · USD
4.340
-0.050 (-1.14%)
At close: May 30, 2025, 4:00 PM
4.420
+0.080 (1.84%)
After-hours: May 30, 2025, 7:56 PM EDT
-1.14%
Market Cap 255.78M
Revenue (ttm) 201.35M
Net Income (ttm) -44.25M
Shares Out 58.93M
EPS (ttm) -0.76
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 234,824
Open 4.360
Previous Close 4.390
Day's Range 4.300 - 4.405
52-Week Range 3.809 - 6.750
Beta 0.69
Analysts Strong Buy
Price Target 15.33 (+253.23%)
Earnings Date May 7, 2025

About VNDA

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson’s disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Ponvory for the treatment of psoriasis and ulcerative colitis. Its pipeline products include HETLIOZ (tasimelteon) ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Apr 12, 2006
Employees 368
Stock Exchange NASDAQ
Ticker Symbol VNDA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for VNDA stock is "Strong Buy." The 12-month stock price forecast is $15.33, which is an increase of 253.23% from the latest price.

Price Target
$15.33
(253.23% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting

WASHINGTON , May 27, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, ...

4 days ago - PRNewsWire

Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025

WASHINGTON , May 16, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in investor meetings at the Mizuho Neuro & Ophthalmology S...

15 days ago - PRNewsWire

Vanda Pharmaceuticals Inc. (VNDA) Q1 2025 Earnings Call Transcript

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q1 2025 Results Conference Call May 7, 2025 4:30 PM ET Company Participants Kevin Moran - CFO Mihael Polymeropoulos - President, Chairman and CEO Tim Williams...

24 days ago - Seeking Alpha

Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results

Fanapt® Q1 2025 total prescriptions (TRx) increased 14% compared to Q1 2024 Fanapt® Q1 2025 new to brand prescriptions (NBRx) increased nearly threefold compared to Q1 2024 Bysanti™ (milsaperidone) ND...

24 days ago - PRNewsWire

Vanda Announces Bysanti™ NDA Filing; FDA Decision Expected in Early 2026

WASHINGTON , May 5, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) informed Vanda that the New Drug Application...

26 days ago - PRNewsWire

Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025

Conference Call and Webcast to Follow WASHINGTON , May 2, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the first quarter 2025 on W...

4 weeks ago - PRNewsWire

FDA Bureaucrats Unlawfully Delay Hearing on Vanda Drug and Falsely Blame Commissioner Makary and the reductions in force at FDA

WASHINGTON , April 23, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda") (Nasdaq: VNDA) today announced that FDA bureaucrats have committed to delay Vanda's request for a hearing on the approv...

5 weeks ago - PRNewsWire

Vanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting

WASHINGTON , April 7, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at the American Academy of Neurology (AAN) Annual Meeting, to be held in San ...

7 weeks ago - PRNewsWire

Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti™ for the Treatments of Acute Bipolar I Disorder and Schizophrenia

WASHINGTON , March 31, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (...

2 months ago - PRNewsWire

Vanda Pharmaceuticals announces the publication of an article titled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S"

WASHINGTON , Feb. 24, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the publication of an article entitled "Potential ASO-based personalized treatment for Char...

3 months ago - PRNewsWire

Vanda Pharmaceuticals, Inc. (VNDA) Q4 2024 Earnings Call Transcript

Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA) Q4 2024 Earnings Conference Call February 13, 2025 4:30 PM ET Company Participants Kevin Moran - SVP, CFO & Treasurer Mihael Polymeropoulos - Founder, Presid...

3 months ago - Seeking Alpha

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

Q4 2024 total revenues of $53.2 million, +17% compared to Q4 2023 Q4 2024 Fanapt® net product sales of $26.6 million, +18% compared to Q4 2023 Full year 2024 total revenues of $198.8 million, +3% comp...

3 months ago - PRNewsWire

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

Conference Call and Webcast to Follow WASHINGTON , Feb. 5, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the fourth quarter and ful...

4 months ago - PRNewsWire

Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis

Highlights faulty FDA review WASHINGTON , Jan. 27, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provides an update on the tradipitant development program. Gastroparesis...

4 months ago - PRNewsWire

Vanda's Letter to FDA Commissioner Highlights Faulty Gastroparesis NDA Review

WASHINGTON , Jan. 8, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) letter to FDA Commissioner highlights faulty gastroparesis NDA review. As previously reported, Vanda has sou...

5 months ago - PRNewsWire

Vanda Pharmaceuticals: Net-Net Status Presents A Trading Opportunity

Vanda Pharmaceuticals has returned to net-net status. Vanda has been building out their sales team to ramp up Fanapt and PONVORY distribution. I'm interested in buying the stock prior to FY 2024 resul...

5 months ago - Seeking Alpha

Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VGT-1849A, a Novel and Selective Antisense Oligonucleotide Candidate for the Treatment of Polycythemia Vera

WASHINGTON , Dec. 20, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for VGT-184...

5 months ago - PRNewsWire

Glancy Prongay & Murray LLP Announces Investigation of Vanda Pharmaceuticals Inc.

NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) concerning the Company and its directors' and officers' possible...

5 months ago - Business Wire

Vanda Pharmaceuticals Announces Participation at November 2024 Investor Conferences

WASHINGTON , Nov. 12, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the following upcoming investor conferences in Novembe...

7 months ago - PRNewsWire

Vanda Pharmaceuticals Inc. (VNDA) Q3 2024 Earnings Call Transcript

Vanda Pharmaceuticals Inc. (VNDA) Q3 2024 Earnings Call Transcript

7 months ago - Seeking Alpha

Vanda Pharmaceuticals Reports Third Quarter 2024 Financial Results

Revenues for Q3 2024 were $47.7 million, an increase of 23% compared to Q3 2023 Financial Guidance revised for Full Year 2024, raising the midpoint of revenue and cash ranges Fanapt® launch in bipolar...

7 months ago - PRNewsWire

Over 200% Stock Upside - Vanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: Analyst

HC Wainwright initiated coverage on Vanda Pharmaceuticals, Inc. VNDA, a commercial-stage biopharmaceutical firm primarily focusing on neurological and neuropsychiatry disorders.

7 months ago - Benzinga

Vanda Pharmaceuticals to Announce Third Quarter 2024 Financial Results on November 6, 2024

Conference Call and Webcast to Follow WASHINGTON , Oct. 30, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2024 on...

7 months ago - PRNewsWire

Vanda Pharmaceuticals Confirms Receipt of Economically Identical Unsolicited, Non-Binding Proposal from Cycle Group Holdings Ltd.

Board Has Determined That Latest Proposal Is Not in the Best Interests of the Company or Stockholders WASHINGTON , Oct. 14, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (...

8 months ago - PRNewsWire

Cycle Pharma maintains takeover offer for Vanda Pharmaceuticals

UK-based Cycle Pharmaceuticals on Monday reaffirmed its offer to buy Vanda Pharmaceuticals in a deal that values the US drugmaker at $488 million, despite a regulatory setback for its stomach conditio...

8 months ago - Reuters